Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1B | P00325 | 4/20 | 0.38 |
| ▸ | ADH1A | P07327 | 4/20 | 0.38 |
| ▸ | ADH1C | P00326 | 3/20 | 0.38 |
| ▸ | NAMPT | P43490 | 3/20 | 0.38 |
| ▸ | ADH7 | P40394 | 2/20 | 0.38 |
| ▸ | ADH4 | P08319 | 1/20 | 0.36 |
| ▸ | IDH1 | O75874 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 4/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | BRD2 | P25440 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | IL1B | P01584 | 2/20 | 0.31 |
| ▸ | HTR5A | P47898 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21134428 | 0.87 | ADH1B (0.37) | ADH1BADH1AADH1CADH7ADH4 | |
| SCHEMBL14684463 | 0.79 | NAMPT (0.40) | NAMPTIDH1GRM5BRD4BRD2 | |
| SCHEMBL12840777 | 0.79 | NAMPT (0.40) | NAMPTIDH1GRM5BRD4BRD2 | |
| SCHEMBL12797531 | 0.79 | NAMPT (0.40) | NAMPTIDH1GRM5BRD4BRD2 | |
| SCHEMBL5638943 | 0.79 | ADH1B (0.38) | ADH1BADH1AADH1CADH7ADH4 | |
| SCHEMBL5636760 | 0.78 | GAA (0.36) | ADH1BADH1AADH1CADH7ADH4 | |
| SCHEMBL5637448 | 0.77 | ADH1B (0.33) | ADH1BADH1AADH1CADH7ADH4 | |
| SCHEMBL5641306 | 0.77 | ADH1B (0.33) | ADH1BADH1AADH1CADH7ADH4 | |
| SCHEMBL5639365 | 0.75 | NAMPT (0.38) | NAMPTIDH1GRM5BRD4BRD2 | |
| SCHEMBL5637549 | 0.75 | ADH1B (0.34) | ADH1BADH1AADH1CADH7ADH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7220856-B2 | Substituted quinoline CCR5 receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-05-22 | — | — | US | disclosed |
| EP-1534681-A1 | SUBSTITUTED QUINOLINE CCR5 RECEPTOR ANTAGONISTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-06-01 | — | — | EP | disclosed |
| US-20040072818-A1 | Substituted quinoline CCR5 receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-04-15 | — | — | US | disclosed |
| WO-2004002960-A1 | SUBSTITUTED QUINOLINE CCR5 RECEPTOR ANTAGONISTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072818-A1 | Substituted quinoline CCR5 receptor antagonists | CCR5, CXCR3, CCR2 | ADH1B 1924/4885ADH1A 910/4885ADH1C 764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.